Cardiology
When a Cardiology Trial ‘Wins’, What Actually Improved?
Cardiovascular trials are increasingly using hierarchical composite endpoints to capture treatment effects across survival, hospitalisation, symptoms and quality of life. The approach can reflect clinical priorities more effectively than conventional time-to-first-event analysis, but a positive win ratio does not necessarily mean fewer deaths or cardiovascular events.
Can an hour of exercise undo eight hours of sitting? The heart-health evidence is more complicated
Borderline blood pressure is not harmless. The mistakes that let cardiovascular risk build quietly
The first oral PCSK9 inhibitor is approved. A pill will not fix cholesterol access by itself
Oral GLP-1 drugs could widen access, but high prices may do the opposite
The ovaries were never the whole story: PMOS linked to heart attacks and strokes in more than two million women
The Novo Nordisk Foundation is going global on cardiometabolic disease.
Plastic in the coronary bloodstream: micro- and nanoplastics raise a new cardiovascular warning
Military recruits appear to face far more sudden cardiac death than athletes. Screening still depends on the country
Singapore wants healthcare AI that does not think like the West. Cardiometabolic care is its first real test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases